Opus Genetics FY2025 net loss narrows 14% to USD 49.59 million on revenue up 29% to USD 14.2 million

Reuters03-10

<a href="https://laohu8.com/S/IRD">Opus Genetics</a> FY2025 net loss narrows 14% to USD 49.59 million on revenue up 29% to USD 14.2 million

Opus Genetics reported a FY 2025 net loss of USD 49.6 million, compared with a FY 2024 net loss of USD 57.5 million. FY 2025 license and collaborations revenue rose 29% to USD 14.2 million, driven by its Viatris collaboration for reimbursement of R&D services. FY 2025 R&D expenses increased 15% to USD 30.8 million due to higher clinical research, toxicology, payroll and professional services costs, partly offset by lower manufacturing and regulatory costs. FY 2025 G&A expenses rose 21% to USD 22 million on higher legal and patent-related, payroll, public-company and professional services costs. Opus Genetics ended FY 2025 with USD 45.1 million in cash and cash equivalents and said it expects aggregate cash resources of USD 70.1 million, including a USD 25 million private placement completed after year-end, to fund operations into the first half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603100700PRIMZONEFULLFEED9668682) on March 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618934455?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618934455","market":"nz","top_or_hot":-1,"title":"Opus Genetics FY2025 net loss narrows 14% to USD 49.59 million on revenue up 29% to USD 14.2 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IRD\">Opus Genetics</a> FY2025 net loss narrows 14% to USD 49.59 million on revenue up 29% to USD 14.2 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Opus Genetics reported a FY 2025 net loss of USD 49.6 million, compared with a FY 2024 net loss of USD 57.5 million. FY 2025 license and collaborations revenue rose 29% to USD 14.2 million, driven by its Viatris collaboration for reimbursement of R&amp;D services. FY 2025 R&amp;D expenses increased 15% to USD 30.8 million due to higher clinical research, toxicology, payroll and professional services costs, partly offset by lower manufacturing and regulatory costs. FY 2025 G&amp;A expenses rose 21% to USD 22 million on higher legal and patent-related, payroll, public-company and professional services costs. Opus Genetics ended FY 2025 with USD 45.1 million in cash and cash equivalents and said it expects aggregate cash resources of USD 70.1 million, including a USD 25 million private placement completed after year-end, to fund operations into the first half of 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603100700PRIMZONEFULLFEED9668682) on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opus Genetics FY2025 net loss narrows 14% to USD 49.59 million on revenue up 29% to USD 14.2 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpus Genetics FY2025 net loss narrows 14% to USD 49.59 million on revenue up 29% to USD 14.2 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IRD\">Opus Genetics</a> FY2025 net loss narrows 14% to USD 49.59 million on revenue up 29% to USD 14.2 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Opus Genetics reported a FY 2025 net loss of USD 49.6 million, compared with a FY 2024 net loss of USD 57.5 million. FY 2025 license and collaborations revenue rose 29% to USD 14.2 million, driven by its Viatris collaboration for reimbursement of R&amp;D services. FY 2025 R&amp;D expenses increased 15% to USD 30.8 million due to higher clinical research, toxicology, payroll and professional services costs, partly offset by lower manufacturing and regulatory costs. FY 2025 G&amp;A expenses rose 21% to USD 22 million on higher legal and patent-related, payroll, public-company and professional services costs. Opus Genetics ended FY 2025 with USD 45.1 million in cash and cash equivalents and said it expects aggregate cash resources of USD 70.1 million, including a USD 25 million private placement completed after year-end, to fund operations into the first half of 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603100700PRIMZONEFULLFEED9668682) on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL90B92F:1","article_id":"2618934455","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618934455","pubTimestamp":1773140760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Opus Genetics reported a FY 2025 net loss of USD 49.6 million, compared with a FY 2024 net loss of USD 57.5 million. FY 2025 license and collaborations revenue rose 29% to USD 14.2 million, driven by its Viatris collaboration for reimbursement of R&D services. FY 2025 R&D expenses increased 15% to USD 30.8 million due to higher clinical research, toxicology, payroll and professional services costs, partly offset by lower manufacturing and regulatory costs. FY 2025 G&A expenses rose 21% to USD 22 million on higher legal and patent-related, payroll, public-company and professional services costs. Opus Genetics ended FY 2025 with USD 45.1 million in cash and cash equivalents and said it expects aggregate cash resources of USD 70.1 million, including a USD 25 million private placement completed after year-end, to fund operations into the first half of 2028.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4007":"制药","IRD":"OPUS GENETICS INC","BK4583":"猴痘概念","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","VTRS":"Viatris Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC"},"translate_title":"Opus Genetics 2025财年净亏损收窄14%至4959万美元，收入增长29%至1420万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"IRD":0.9,"VTRS":0.9},"content_text":"Opus Genetics FY2025 net loss narrows 14% to USD 49.59 million on revenue up 29% to USD 14.2 million\n    \n\n        Opus Genetics reported a FY 2025 net loss of USD 49.6 million, compared with a FY 2024 net loss of USD 57.5 million. FY 2025 license and collaborations revenue rose 29% to USD 14.2 million, driven by its Viatris collaboration for reimbursement of R&D services. FY 2025 R&D expenses increased 15% to USD 30.8 million due to higher clinical research, toxicology, payroll and professional services costs, partly offset by lower manufacturing and regulatory costs. FY 2025 G&A expenses rose 21% to USD 22 million on higher legal and patent-related, payroll, public-company and professional services costs. Opus Genetics ended FY 2025 with USD 45.1 million in cash and cash equivalents and said it expects aggregate cash resources of USD 70.1 million, including a USD 25 million private placement completed after year-end, to fund operations into the first half of 2028.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603100700PRIMZONEFULLFEED9668682) on March 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618934455","isCrawlerRequest":true}